COX Nicox SA

Number of voting rights as of February 28, 2021

Number of voting rights as of February 28, 2021

Nicox SA

Société anonyme with a registered capital of € 37,103,985

Head Office:

DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis 

R.C.S. GRASSE 403.942.642

On March 2, 2021,

MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS

(Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF)

 As of February 28, 2021
Total number of shares composing the share capital37,103,985
Total number of voting rights37,103,985
Total number of voting rights, calculated based on the total number of shares, including the shares deprived of voting rights37,103,985

---------------



Phone: 00

Fax : 99

 

Attachment



EN
02/03/2021

Underlying

COXNicox SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nicox SA

 PRESS RELEASE
Free
COX NICOX SA

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclu...

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 millionTiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit royalties elsewhere Kowa wil...

July 17, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 mi...

Nicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 millions d’euros pour les droits exclusifs du traitement du glaucome NCX 470 aux Etats-Unis et dans l’ensemble des territoires non-licenciés Communiqué de presseNicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 millions d’euros pour les droits exclusifs du traitement du glaucome NCX 470 aux Etats-Unis et dans l’ensemble des territoires non-licenciés Un paiement initial de 7,5 millions d’euros, avec des paiements d’étapes de développement et de commercialisation pouvant atteindre un total de 191,5 millions...

July 17, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clin...

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in the U.S. targeted for H1 2026 June 30, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient has completed the Denali Phase 3 trial, evaluating the efficacy and safety of NCX 470, its lead comp...

June 30, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox annonce que le dernier patient a terminé l’essai clinique de Pha...

Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470 Communiqué de presseNicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470 Les premiers résultats sont attendus entre mi-août et mi-septembre 2025 L’autorisation de mise sur le marché (NDA) au Etats-Unis est prévu pour le premier semestre 2026 30 Juin 2025 – publication à 7H30 Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que le...

June 30, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting ...

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative Press Release Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representativeJune 6, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, reminds its shareholders that the Ordinary and Extraordinary General Meeting will be held on Friday, June 27, 2025 at 2:30 p.m., at the Company’s headquarters locate...

June 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch